Focused On-demand Library for ER membrane protein complex subunit 10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q5UCC4

UPID:

EMC10_HUMAN

Alternative names:

Hematopoietic signal peptide-containing membrane domain-containing protein 1

Alternative UPACC:

Q5UCC4; Q5UCC6; Q69YT5; Q6UWP3; Q86YL4; Q8N541

Background:

ER membrane protein complex subunit 10, also known as Hematopoietic signal peptide-containing membrane domain-containing protein 1, plays a crucial role in the endoplasmic reticulum membrane. It facilitates the insertion of newly synthesized membrane proteins, accommodating those with weakly hydrophobic or destabilizing features. This protein is essential for the cotranslational and post-translational insertion of multi-pass and tail-anchored proteins, respectively, influencing the topology of multi-pass membrane proteins like G protein-coupled receptors.

Therapeutic significance:

Linked to Neurodevelopmental disorder with dysmorphic facies and variable seizures, ER membrane protein complex subunit 10's understanding could pave the way for innovative therapeutic strategies targeting neurodevelopmental disorders.